Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results

Entrada Therapeutics (NASDAQ:TRDA) posted its earnings results on Thursday. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.66) by $0.69, Zacks reports. The company had revenue of $12.25 million during the quarter, compared to the consensus estimate of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%.

Entrada Therapeutics Price Performance

Entrada Therapeutics stock opened at $11.94 on Friday. Entrada Therapeutics has a fifty-two week low of $11.35 and a fifty-two week high of $21.79. The firm has a fifty day moving average price of $14.18 and a two-hundred day moving average price of $16.21. The firm has a market cap of $446.79 million, a price-to-earnings ratio of 7.51 and a beta of -0.17.

Analysts Set New Price Targets

TRDA has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research note on Tuesday. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm initiated coverage on Entrada Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $29.00 price target for the company. Finally, Oppenheimer raised their price objective on Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a research note on Wednesday, November 6th.

Insider Activity

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 5,000 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $20.00, for a total value of $100,000.00. Following the completion of the sale, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at $1,476,980. This represents a 6.34 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $20.77, for a total transaction of $476,359.95. Following the transaction, the insider now owns 4,402,849 shares in the company, valued at approximately $91,447,173.73. The trade was a 0.52 % decrease in their position. The disclosure for this sale can be found here. 7.59% of the stock is currently owned by company insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.